Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Gyre Therapeutics Inc GYRE

Healthcare Biotechnology
Gyre Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of F351 (Hydronidone) for the treatment of MASH-associated fibrosis in the United States. It is also advancing a diverse pipeline in the PRC through its indirect controlling interest in Gyre Pharmaceuticals, including ETUARY therapeutic expansions, F573, F528, and F230. F351... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:GYRE)

Gyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

GlobeNewswire 8 days ago

Gyre Therapeutics Announces NMPA Approval for Clinical Trial Evaluating Pirfenidone Capsules in Oncology-Related Pulmonary Complications

GlobeNewswire March 31, 2025

Gyre Therapeutics Announces Publication of Protocol for Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis in Journal of Clinical and Translational Hepatology

GlobeNewswire March 27, 2025

Gyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

GlobeNewswire March 17, 2025

Gyre Therapeutics Announces the Appointment of Ping Zhang to Board of Directors

GlobeNewswire January 6, 2025

Gyre Therapeutics Reports Third Quarter 2024 and Year-To-Date Financial Results and Provides Business Update

GlobeNewswire November 13, 2024

Gyre Therapeutics Announces Last Patient Completed Pivotal Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis

GlobeNewswire October 22, 2024

Gyre Therapeutics to Present at 8th Annual H.C. Wainwright MASH Investor Conference

GlobeNewswire October 1, 2024

Gyre Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference

GlobeNewswire September 4, 2024
View More News ››

Opinion & Analysis (NDAQ:GYRE)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:GYRE)

Gyre Therapeutics (GYRE): A Diversified Pipeline Tackling Ch

Solid play here. GYRE looking interesting with their anti-fibrotic pipeline and strong China market presence. F351 Phase 3 trial for...
MikeTester - January 23, 2025
View more Bullboard ››

AJA Health and Wellness Inc.

AJA Health and Wellness Inc.

AJA Health and Wellness Inc. is an India-based health and wellness company. The Company operates through its subsidiaries ...
View More »